Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 2,652 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Clear all
Recruiting Phase 4 Interventional

Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study

NCT07508124
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
betamethasone valerate 0.1% cream, Placebo cream
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Months to 5 Months · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza With ILUX for Treatment of MGD

NCT04658927
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
Dexamethasone, 0.4mg, Prednisone acetate, Control
Drug · Other
Lead sponsor
Warrenville Eyecare
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Not applicable Interventional

Blue Light Photodynamic Therapy Treatment for Distal and Lateral Subungual Toenail Onychomycosis

NCT03022903
View directory record Official record
Conditions
Toenail Onychomycosis, Distal and Lateral Subungual Toenail Onychomycosis
Interventions
Aminolevulinic Acid (ALA)
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 29, 2026, 9:43 AM EDT
Terminated Phase 4 Interventional Results available

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

NCT05479123
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Propranolol three times a day, Propranolol twice a day, Timolol
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 18 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

NCT03235024
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 29, 2026, 9:43 AM EDT
Active, not recruiting Phase 2 Interventional

Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL

NCT05555862
View directory record Official record
Conditions
Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection, Anal Dysplasia, HPV Disease
Interventions
Artesunate, Placebo
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 29, 2026, 9:43 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

NCT05493488
View directory record Official record
Conditions
Tinea Pedis
Interventions
DBI-001 Gel, DBI-002 Gel, Aqueous Gel
Biological
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Portland, Oregon • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 29, 2026, 9:43 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure

NCT03126539
View directory record Official record
Conditions
Aging
Interventions
Sulforaphane, Narrow-band Ultraviolet B exposure, 4 mm skin punch biopsy
Drug · Radiation · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Phase 2 Interventional

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

NCT03381625
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
BMX-010, Placebo
Drug
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Encino, California • Denver, Colorado • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 29, 2026, 9:43 AM EDT
Active, not recruiting Phase 2 Interventional

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

NCT02971891
View directory record Official record
Conditions
Cutaneous Common Warts
Interventions
CLS006 (Furosemide) Topical Gel, Vehicle Topical Gel
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
2 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 29, 2026, 9:43 AM EDT
Withdrawn Phase 3 Interventional

Topical Allstate and Nasal Allergen Challenge

NCT01231724
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Allstate Nasal Spray, Placebo Nasal Spray
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements

NCT03760042
View directory record Official record
Conditions
Healthy
Interventions
Within-Subject Active vs. Placebo Topical Applications
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies

NCT03126968
View directory record Official record
Conditions
Lung Transplant; Complications, Mechanical, Lung Transplant; Complications, Bleeding, Hemoptysis
Interventions
Topical epinephrine, Placebos
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 29, 2026, 9:43 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation

NCT06966388
View directory record Official record
Conditions
Breast Cancer
Interventions
Azelaic Acid
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine

NCT00276068
View directory record Official record
Conditions
Vulvar Disease
Interventions
topical lidocaine + oral desipramine, and/or placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2007 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Phase 4 Interventional Results available

Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis

NCT01111123
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%), Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea

NCT05278624
View directory record Official record
Conditions
Rosacea
Interventions
Roflumilast Cream
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Not applicable Interventional Results available

MediHoney for Radiation Dermatitis

NCT02234479
View directory record Official record
Conditions
Breast Cancer, Radiation Dermatitis
Interventions
Hydrophor (Group A), MediHoney (Group B)
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 29, 2026, 9:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)

NCT04305184
View directory record Official record
Conditions
Chronic Tympanic Membrane Perforation
Interventions
ASP0598, Placebo
Drug · Other
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Palo Alto, California • Torrance, California • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 29, 2026, 9:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers

NCT07396376
View directory record Official record
Conditions
Diabetic Foot Ulcer, Wagner Grade 1 - 2, Chronic Wound, Open Wound
Interventions
ELU42 Topical Spray
Drug
Lead sponsor
Eluciderm Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
O'Fallon, Illinois • Springfield, Illinois • Oradell, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

NCT00550589
View directory record Official record
Conditions
Anal Cancer, Precancerous Condition
Interventions
cidofovir, DNA methylation analysis, gene expression analysis, polymerase chain reaction, biopsy, histopathologic examination
Drug · Genetic · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 29, 2026, 9:43 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Topical Cannabidiol Application and Skin Vascular Reactivity

NCT05456113
View directory record Official record
Conditions
Effect of Drug
Interventions
Cannabidiol
Biological
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 29, 2026, 9:43 AM EDT
Completed Phase 2 Interventional

Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED

NCT02390960
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Sildenafil Cream, Placebo Cream, Penile Plethysmography (RigiScan)
Drug · Device
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
San Diego, California • New Orleans, Louisiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 29, 2026, 9:43 AM EDT